STAR-0602 is under clinical development by Marengo Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STAR-0602’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STAR-0602 is under development for the treatment of hematological malignancies, solid tumors, triple negative breast cancer, epithelial ovarian cancer, metastatic castration-resistance prostate cancer, metastatic colorectal cancer and non-small cell lung cancer. The drug candidate is developed based on universal targeted immunotherapy (UniTI) platform. The drug candidate is administered through intravenous route.
Marengo Therapeutics overview
Marengo Therapeutics (Marengo) formerly, Elstar Therapeutics is developing first-in-class immuno-oncology therapeutics. The company utilizes its Universal Targeted Immunotherapy (UniTI) drug discovery platform to develop cancer immunotherapy pipeline programs. UniTI produces bi-, tri-, and tetra-functional antibody-based molecules which can employ dual-targeting of independent cell surface tumor antigens and engage multiple innate and adaptive immunological mechanisms to attack diseased cells. The company is funded by Apple Tree Partners. Marengo is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of STAR-0602’s drug-specific PTSR and LoA scores, buy the report here.